Barclays 28th Annual Global Healthcare Conference March 12, 2026 11:30 AM EDTCompany ParticipantsDinesh Patel - ...

While the FDA mulls whether to approve Protagonist Therapeutics’ hematology asset, the biotech is thinking it will pocket $400 million rather than split U.S. profits with its partner Takeda. | While ...

Takeda Pharmaceutical Company Limited (NYSE:TAK) is one of the most promising stocks under $20. On March 2, Takeda and Protagonist Therapeutics announced that the US FDA accepted the New Drug ...

Delving into Protagonist Therapeutics's Background. Protagonist Therapeutics Inc is a clinical-stage biopharmaceutical company having a proprietary technology platform that enable ...

Ratings for Protagonist Therapeutics (NASDAQ:PTGX) were provided by 8 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view ...

NEWARK, CA / ACCESS Newswire / February 24, 2026 / Protagonist Therapeutics, Inc. ("Protagonist" or the "Company") ...

Protagonist Therapeutics is a discovery through late-stage development biopharmaceutical company. Two novel peptides derived from Protagonist's proprietary discovery platform are currently in advanced ...

Protagonist Therapeutics is a clinical-stage biotechnology company that uses proprietary peptide technology to address unmet medical needs in hematology and immunology. It focuses on patients with ...

) has been revised to $91.65 / share. This is an increase of 16.48% from the prior estimate of $78.69 dated November 7, 2025. The price target is an average of many targets provided by analysts. The ...

Webcast: https://jpmorgan.metameetings.net/events/healthcare26/sessions/317262-protagonist-therapeutics-inc/webcast?gpu_only=true&kiosk=true If you are interested in ...

Transaction value based on SEC Form 4 reported price ($82.48); post-transaction value based on Jan. 20, 2026 market close ($82.48). Protagonist Therapeutics is a clinical-stage biotechnology company ...